In light of an Indian court’s refusal to grant a patent to the leukemia drug Gleevec, CFR senior fellow Thomas Bollyky wrote yesterday about the tension between pharmaceutical firms seeking compensation for their products and developing countries seeking to make drugs more affordable to their populations. As he argues:
First, multinational drugs firms can, and should, reduce the cost of R&D, which would enable these firms to better function in the increasingly price-sensitive global marketplace for drugs... Second, multinational firms must realize that there are low-income segments of the global marketplace that these firms cannot serve, but whose health needs must be met for international support of the pharmaceutical, trade, and IP system to persist. These companies must again be willing to license their patents to emerging country generic manufacturers better able to meet the low-cost, high-volume treatment needs of their poor.
You can read the full article here on TheAtlantic.com.